The addition of daratumumab to maintenance lenalidomide extended PFS for patients who underwent stem cell transplant for newly diagnosed multiple myeloma, according to study results.
The combination reduced risk for disease progression or death by 47% compared with lenalidomide alone, results of the randomized phase 3 AURIGA trial showed.
“This is a practice-informing trial that supports the addition of daratumumab not only in induction/consolidation, but also in maintenance,” Ashraf Z. Badros, MBCHB, director of the multiple myeloma service at University of Maryland Marlene and
